Your genes and your heart pill: study seeks to personalize treatment
NCT ID NCT07439952
Summary
This study aims to understand why patients respond differently to the heart medication mavacamten, which treats a condition called obstructive hypertrophic cardiomyopathy. Researchers will collect genetic and health data from 300 patients already taking the drug to see if a person's genetic makeup predicts how well the treatment works or if side effects occur. The goal is to help doctors better personalize dosing for future patients based on their genetics.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP, Ambroise Paré
Boulogne-Billancourt, 92100, France
Contact
Contact Email: •••••@•••••
-
APHP, Bicêtre hospital
Le Kremlin-Bicêtre, France
Contact Email: •••••@•••••
Contact
-
APHP, La Pitié Salpetriere hospital
Paris, 75013, France
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.